In my first article, I talked about Novavax's (NASDAQ:NVAX) revolutionary rapid formula VLP technology, a process that reduces the timeline to produce an effective vaccine by up to 83%. And in my most recent article, I addressed the proposed acquisition of adjuvant maker Isconova and expressed some reservations about the real motivations behind that move. Those apprehensions had to do with safety data from the RSV Phase 1 trial in the elderly. Novavax has responded.
A scant three days later, top-line results were revealed. And what the numbers suggest is that the acquisition of Isconova has nothing to do with tolerability data in either RSV trial. It may have to do with having tax write-offs for weekend ski...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|